Non-Alcoholic Fatty Liver Disease Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Eli Lilly and Company, Pfizer, Boehringer Ingelheim, AstraZeneca, Inventiva

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Non-Alcoholic Fatty Liver Disease pipeline constitutes 90+ key companies continuously working towards developing 100+ Non-Alcoholic Fatty Liver Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Non-Alcoholic Fatty Liver Disease Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Alcoholic Fatty Liver Disease Market.

The Non-Alcoholic Fatty Liver Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Non-Alcoholic Fatty Liver Disease Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Non-Alcoholic Fatty Liver Disease treatment therapies with a considerable amount of success over the years.

*
Non-Alcoholic Fatty Liver Disease companies working in the treatment market are MediciNova, Eli Lilly and Company, AstraZeneca, Inventiva Pharma, Oasis Pharmaceuticals, LLC, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Hepion Pharmaceuticals, Inc., and others, are developing therapies for the Non-Alcoholic Fatty Liver Disease treatment

*
Emerging Non-Alcoholic Fatty Liver Disease therapies in the different phases of clinical trials are- MN-001, LY3885125, AZD7503, Lanifibranor, OA-235i, Resmetirom, BMN 255, GSK4532990, Saroglitazar Magnesium 4 mg Tablet, Efruxifermin, PF-06865571, BI 3006337, DD01, Efinopegdutide, HU6, Rencofilstat, and others are expected to have a significant impact on the Non-Alcoholic Fatty Liver Disease market in the coming years.

*
In October 2024, Madrigal Pharmaceuticals, a biopharmaceutical company based in the US, has completed patient enrollment for a trial of Rezdiffra (resmetirom), a potential treatment for compensated non-alcoholic steatohepatitis (NASH) cirrhosis. The MAESTRO-NASH OUTCOMES study is a double-blind, randomized, placebo-controlled Phase III trial that includes 845 patients with compensated NASH cirrhosis and three metabolic risk factors.

Non-Alcoholic Fatty Liver Disease Overview

Non-Alcoholic Fatty Liver Disease (NAFLD) is a condition characterized by the accumulation of fat in the liver cells, not caused by excessive alcohol consumption. It encompasses a spectrum of liver disorders ranging from simple fatty liver (steatosis) to more severe conditions like non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis.

Get a Free Sample PDF Report to know more about Non-Alcoholic Fatty Liver Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight [https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Non-Alcoholic Fatty Liver Disease Drugs Under Different Phases of Clinical Development Include:

*
MN-001: MediciNova

*
LY3885125: Eli Lilly and Company

*
AZD7503: AstraZeneca

*
Lanifibranor: Inventiva Pharma

*
OA-235i: Oasis Pharmaceuticals, LLC

*
Resmetirom: Madrigal Pharmaceuticals, Inc.

*
BMN 255: BioMarin Pharmaceutical

*
GSK4532990: GlaxoSmithKline

*
Saroglitazar Magnesium 4 mg Tablet: Zydus Therapeutics Inc.

*
Efruxifermin: Akero Therapeutics, Inc

*
PF-06865571: Pfizer

*
BI 3006337: Boehringer Ingelheim

*
DD01: Neuraly, Inc.

*
Efinopegdutide: Merck Sharp & Dohme LLC

*
HU6: Rivus Pharmaceuticals, Inc.

*
Rencofilstat: Hepion Pharmaceuticals, Inc.

Non-Alcoholic Fatty Liver Disease Route of Administration

Non-Alcoholic Fatty Liver Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Intra-articular

*
Intraocular

*
Intrathecal

*
Intravenous

*
Ophthalmic

*
Oral

*
Parenteral

*
Subcutaneous

*
Topical

*
Transdermal

Non-Alcoholic Fatty Liver Disease Molecule Type

Non-Alcoholic Fatty Liver Disease Products have been categorized under various Molecule types, such as

*
Oligonucleotide

*
Peptide

*
Small molecule

Non-Alcoholic Fatty Liver Disease Pipeline Therapeutics Assessment

*
Non-Alcoholic Fatty Liver Disease Assessment by Product Type

*
Non-Alcoholic Fatty Liver Disease By Stage and Product Type

*
Non-Alcoholic Fatty Liver Disease Assessment by Route of Administration

*
Non-Alcoholic Fatty Liver Disease By Stage and Route of Administration

*
Non-Alcoholic Fatty Liver Disease Assessment by Molecule Type

*
Non-Alcoholic Fatty Liver Disease by Stage and Molecule Type

DelveInsight's Non-Alcoholic Fatty Liver Disease Report covers around 100+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Non-Alcoholic Fatty Liver Disease product details are provided in the report. Download the Non-Alcoholic Fatty Liver Disease pipeline report to learn more about the emerging Non-Alcoholic Fatty Liver Disease therapies [https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Non-Alcoholic Fatty Liver Disease Therapeutics Market include:

Key companies developing therapies for Non-Alcoholic Fatty Liver Disease are - Eli Lilly and Company, Pfizer, Boehringer Ingelheim, AstraZeneca, Inventiva Pharma, Oasis Pharmaceuticals, LLC, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., MediciNova, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Hepion Pharmaceuticals, Inc., and others.

Non-Alcoholic Fatty Liver Disease Pipeline Analysis:

The Non-Alcoholic Fatty Liver Disease pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Non-Alcoholic Fatty Liver Disease with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Alcoholic Fatty Liver Disease Treatment.

*
Non-Alcoholic Fatty Liver Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Non-Alcoholic Fatty Liver Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Alcoholic Fatty Liver Disease market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Non-Alcoholic Fatty Liver Disease drugs and therapies [https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Non-Alcoholic Fatty Liver Disease Pipeline Market Drivers

*
Rise in prevalence of NAFLD, large number of drugs are currently being evaluated, growing Research and Development Activities are some of the important factors that are fueling the Non-Alcoholic Fatty Liver Disease Market.

Non-Alcoholic Fatty Liver Disease Pipeline Market Barriers

*
However, lack of effective strategies for the prevention and effective treatment of NAFLD, relying on biopsies makes NASH diagnosis a difficult task and other factors are creating obstacles in the Non-Alcoholic Fatty Liver Disease Market growth.

Scope of Non-Alcoholic Fatty Liver Disease Pipeline Drug Insight

*
Coverage: Global

*
Key Non-Alcoholic Fatty Liver Disease Companies: MediciNova, Eli Lilly and Company, AstraZeneca, Inventiva Pharma, Oasis Pharmaceuticals, LLC, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Hepion Pharmaceuticals, Inc., and others

*
Key Non-Alcoholic Fatty Liver Disease Therapies: MN-001, LY3885125, AZD7503, Lanifibranor, OA-235i, Resmetirom, BMN 255, GSK4532990, Saroglitazar Magnesium 4 mg Tablet, Efruxifermin, PF-06865571, BI 3006337, DD01, Efinopegdutide, HU6, Rencofilstat, and others

*
Non-Alcoholic Fatty Liver Disease Therapeutic Assessment: Non-Alcoholic Fatty Liver Disease current marketed and Non-Alcoholic Fatty Liver Disease emerging therapies

*
Non-Alcoholic Fatty Liver Disease Market Dynamics: Non-Alcoholic Fatty Liver Disease market drivers and Non-Alcoholic Fatty Liver Disease market barriers

Request for Sample PDF Report for Non-Alcoholic Fatty Liver Disease Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Non-Alcoholic Fatty Liver Disease Report Introduction

2. Non-Alcoholic Fatty Liver Disease Executive Summary

3. Non-Alcoholic Fatty Liver Disease Overview

4. Non-Alcoholic Fatty Liver Disease- Analytical Perspective In-depth Commercial Assessment

5. Non-Alcoholic Fatty Liver Disease Pipeline Therapeutics

6. Non-Alcoholic Fatty Liver Disease Late Stage Products (Phase II/III)

7. Non-Alcoholic Fatty Liver Disease Mid Stage Products (Phase II)

8. Non-Alcoholic Fatty Liver Disease Early Stage Products (Phase I)

9. Non-Alcoholic Fatty Liver Disease Preclinical Stage Products

10. Non-Alcoholic Fatty Liver Disease Therapeutics Assessment

11. Non-Alcoholic Fatty Liver Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Non-Alcoholic Fatty Liver Disease Key Companies

14. Non-Alcoholic Fatty Liver Disease Key Products

15. Non-Alcoholic Fatty Liver Disease Unmet Needs

16 . Non-Alcoholic Fatty Liver Disease Market Drivers and Barriers

17. Non-Alcoholic Fatty Liver Disease Future Perspectives and Conclusion

18. Non-Alcoholic Fatty Liver Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nonalcoholic-fatty-liver-disease-pipeline-2024-key-companies-moa-roa-and-clinical-trials-evaluation-by-delveinsight-eli-lilly-and-company-pfizer-boehringer-ingelheim-astrazeneca-inventiva]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.